Home > Journals > Italian Journal of Dermatology and Venereology > Past Issues > Articles online first > Italian Journal of Dermatology and Venereology 2021 Apr 21

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

 

Italian Journal of Dermatology and Venereology 2021 Apr 21

DOI: 10.23736/S2784-8671.21.06952-2

Copyright © 2021 EDIZIONI MINERVA MEDICA

language: English

Dupilumab treatment induced similar improvements in signs, symptoms, and quality of life in adults with moderate-to-severe atopic dermatitis with baseline Eczema Area and Severity Index score < 24 or ≥ 24

Annamaria OFFIDANI 1, Luca STINGENI 2, Iria NERI 3, Filippo CIPRIANI 4, Zhen CHEN 5, Ana B. ROSSI 6, Yufang LU 5, Devis MORETTI 4

1 Dermatology Unit, Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona, Italy; 2 Dermatology Section, Department of Medicine, University of Perugia, Perugia, Italy; 3 Dermatology Unit, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy; 4 Sanofi S.r.l., Milan, Italy; 5 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA; 6 Sanofi Genzyme, Cambridge, MA, USA


PDF


BACKGROUND: In multiple phase 3 trials, dupilumab improved signs, symptoms (including pruritus), and quality-of-life (QoL) in adults with moderate-to-severe atopic dermatitis (AD). In Italy, dupilumab received innovation status but is currently only reimbursed by the National Health Service for adults with Eczema Area Severity Index (EASI) scores ≥24. This analysis assesses disease burden and dupilumab efficacy in adults with EASI scores above and below this threshold.
METHODS: This post-hoc analysis included 299 adults pooled from two, randomized, placebocontrolled, phase 3 trials, LIBERTY AD CAFÉ (NCT02755649) and LIBERTY AD CHRONOS (NCT02260986), who received the approved dupilumab regimen (300mg every 2 weeks) or placebo, with concomitant topical corticosteroids. EASI, Peak Pruritus Numerical Rating Scale (PP-NRS), and Dermatology Life Quality Index (DLQI) were assessed in patients with EASI scores ≥20 to <24 and ≥24 at week 16.
RESULTS: At baseline, EASI was weakly correlated with PP-NRS and DLQI (Spearman’s correlation coefficient = 0.22 and 0.29, respectively). At week 16, in both the EASI<24 and EASI≥24 populations, respectively, significantly more patients vs control achieved: ≥50% improvement in EASI (95.5% vs 55.6%; 80.6% vs 33.1%); ≥3-point improvement in PP-NRS (68.4% vs 35.3%; 55.3% vs 17.7%); and ≥4-point improvement in DLQI (83.3% vs 43.8%; 84.2% vs 41.9%); from baseline. Dupilumab was generally well tolerated with an acceptable safety profile.
CONCLUSIONS: Dupilumab treatment improves signs, symptoms, and QoL in moderate-to-severe AD adults with EASI<24, who can present with high disease burden. Opportunity may exist to use additional parameters to define disease severity and access to new therapies.


KEY WORDS: Atopic dermatitis; Dupilumab; Efficacy; EASI; Adults

top of page